pembrolizumab + quavonlimab + lenvatinib

This is a **combination regimen of pembrolizumab (a PD-1 inhibitor), quavonlimab (a CTLA-4 inhibitor), and lenvatinib (a multi–tyrosine kinase inhibitor)**, evaluated primarily as a first-line treatment for advanced hepatocellular carcinoma (HCC)[1][4][6]. Pembrolizumab blocks programmed death-1 (PD-1) receptor-mediated immune evasion by cancer cells, quavonlimab inhibits cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) to amplify antitumor immune responses, and lenvatinib targets multiple tyrosine kinases including VEGFR, FGFR, PDGFR, RET, and KIT, thereby suppressing tumor angiogenesis and proliferation[1][4][6]. This triplet aims to enhance antitumor efficacy by combining immune checkpoint blockade with targeted suppression of tumor vasculature and growth signals. This fixed-dose coformulation of quavonlimab and pembrolizumab with lenvatinib is being developed for solid tumors, mostly advanced HCC and is also explored in renal cell carcinoma and non-small cell lung cancer[1][2][3][7]. Merck & Co. develops pembrolizumab and quavonlimab, and Eisai develops lenvatinib[4][6].

Brand names

Keytruda (pembrolizumab)Lenvima (lenvatinib)

Other names

pembrolizumab/quavonlimab coformulation + lenvatinib